IN.TO - InMed Pharmaceuticals Inc.

Toronto - Toronto Delayed Price. Currency in CAD

InMed Pharmaceuticals Inc.

815West Hastings Street
Suite 310
Vancouver, BC V6C 1B4

Full Time Employees9

Key Executives

NameTitlePayExercisedYear Born
Mr. Eric A. AdamsPres, CEO & Director504.6kN/A1963
Dr. Eric Chih-Hsien HsuSr. VP of Preclinical R&D294.01kN/AN/A
Mr. Jeffrey M. CharpentierVP of Fin. & Corp. Sec.282.89kN/AN/A
Dr. Sazzad HossainCo-Founder & Member of the Scientific Advisory BoardN/AN/AN/A
Mr. Bruce S. Colwill C.A., CPA, CAChief Financial OfficerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinoid product candidate to treat epidermolysis bullosa. The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of drugs for the treatment of various diseases, including dermatology, ocular, pain, inflammation, pulmonary disease, neurodegenerative, and oncology disease areas. It has an agreement with Pharmaseed Ltd to develop a final formulation for INM-755; and work on IND-enabling pharmacology and toxicology studies. The company also has research agreement with the National Research Council of Canada in for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Corporate Governance

InMed Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.